Homologous recombination deficiency in triple negative breast cancer
Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering t...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Belli, Carmen [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study - Yang, Lin ELSEVIER, 2020, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:45 ; year:2019 ; pages:15-21 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.breast.2019.02.007 |
|---|
| Katalog-ID: |
ELV046533842 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV046533842 | ||
| 003 | DE-627 | ||
| 005 | 20230626013856.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.breast.2019.02.007 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000596.pica |
| 035 | |a (DE-627)ELV046533842 | ||
| 035 | |a (ELSEVIER)S0960-9776(19)30026-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.65 |2 bkl | ||
| 100 | 1 | |a Belli, Carmen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Homologous recombination deficiency in triple negative breast cancer |
| 264 | 1 | |c 2019transfer abstract | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. | ||
| 520 | |a Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. | ||
| 650 | 7 | |a Platinum agent |2 Elsevier | |
| 650 | 7 | |a BRCA mutations |2 Elsevier | |
| 650 | 7 | |a PARP inhibitors |2 Elsevier | |
| 650 | 7 | |a Homologous recombination deficiency |2 Elsevier | |
| 650 | 7 | |a Triple negative breast cancer |2 Elsevier | |
| 700 | 1 | |a Duso, Bruno Achutti |4 oth | |
| 700 | 1 | |a Ferraro, Emanuela |4 oth | |
| 700 | 1 | |a Curigliano, Giuseppe |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Yang, Lin ELSEVIER |t The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |d 2020 |g Amsterdam [u.a.] |w (DE-627)ELV004843835 |
| 773 | 1 | 8 | |g volume:45 |g year:2019 |g pages:15-21 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.breast.2019.02.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.65 |j Chirurgie |q VZ |
| 951 | |a AR | ||
| 952 | |d 45 |j 2019 |h 15-21 |g 7 | ||
| author_variant |
c b cb |
|---|---|
| matchkey_str |
bellicarmendusobrunoachuttiferraroemanue:2019----:ooooseobntodfcecitilng |
| hierarchy_sort_str |
2019transfer abstract |
| bklnumber |
44.65 |
| publishDate |
2019 |
| allfields |
10.1016/j.breast.2019.02.007 doi GBV00000000000596.pica (DE-627)ELV046533842 (ELSEVIER)S0960-9776(19)30026-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Belli, Carmen verfasserin aut Homologous recombination deficiency in triple negative breast cancer 2019transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. Platinum agent Elsevier BRCA mutations Elsevier PARP inhibitors Elsevier Homologous recombination deficiency Elsevier Triple negative breast cancer Elsevier Duso, Bruno Achutti oth Ferraro, Emanuela oth Curigliano, Giuseppe oth Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:45 year:2019 pages:15-21 extent:7 https://doi.org/10.1016/j.breast.2019.02.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 45 2019 15-21 7 |
| spelling |
10.1016/j.breast.2019.02.007 doi GBV00000000000596.pica (DE-627)ELV046533842 (ELSEVIER)S0960-9776(19)30026-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Belli, Carmen verfasserin aut Homologous recombination deficiency in triple negative breast cancer 2019transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. Platinum agent Elsevier BRCA mutations Elsevier PARP inhibitors Elsevier Homologous recombination deficiency Elsevier Triple negative breast cancer Elsevier Duso, Bruno Achutti oth Ferraro, Emanuela oth Curigliano, Giuseppe oth Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:45 year:2019 pages:15-21 extent:7 https://doi.org/10.1016/j.breast.2019.02.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 45 2019 15-21 7 |
| allfields_unstemmed |
10.1016/j.breast.2019.02.007 doi GBV00000000000596.pica (DE-627)ELV046533842 (ELSEVIER)S0960-9776(19)30026-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Belli, Carmen verfasserin aut Homologous recombination deficiency in triple negative breast cancer 2019transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. Platinum agent Elsevier BRCA mutations Elsevier PARP inhibitors Elsevier Homologous recombination deficiency Elsevier Triple negative breast cancer Elsevier Duso, Bruno Achutti oth Ferraro, Emanuela oth Curigliano, Giuseppe oth Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:45 year:2019 pages:15-21 extent:7 https://doi.org/10.1016/j.breast.2019.02.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 45 2019 15-21 7 |
| allfieldsGer |
10.1016/j.breast.2019.02.007 doi GBV00000000000596.pica (DE-627)ELV046533842 (ELSEVIER)S0960-9776(19)30026-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Belli, Carmen verfasserin aut Homologous recombination deficiency in triple negative breast cancer 2019transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. Platinum agent Elsevier BRCA mutations Elsevier PARP inhibitors Elsevier Homologous recombination deficiency Elsevier Triple negative breast cancer Elsevier Duso, Bruno Achutti oth Ferraro, Emanuela oth Curigliano, Giuseppe oth Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:45 year:2019 pages:15-21 extent:7 https://doi.org/10.1016/j.breast.2019.02.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 45 2019 15-21 7 |
| allfieldsSound |
10.1016/j.breast.2019.02.007 doi GBV00000000000596.pica (DE-627)ELV046533842 (ELSEVIER)S0960-9776(19)30026-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Belli, Carmen verfasserin aut Homologous recombination deficiency in triple negative breast cancer 2019transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. Platinum agent Elsevier BRCA mutations Elsevier PARP inhibitors Elsevier Homologous recombination deficiency Elsevier Triple negative breast cancer Elsevier Duso, Bruno Achutti oth Ferraro, Emanuela oth Curigliano, Giuseppe oth Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:45 year:2019 pages:15-21 extent:7 https://doi.org/10.1016/j.breast.2019.02.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 45 2019 15-21 7 |
| language |
English |
| source |
Enthalten in The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study Amsterdam [u.a.] volume:45 year:2019 pages:15-21 extent:7 |
| sourceStr |
Enthalten in The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study Amsterdam [u.a.] volume:45 year:2019 pages:15-21 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Chirurgie |
| institution |
findex.gbv.de |
| topic_facet |
Platinum agent BRCA mutations PARP inhibitors Homologous recombination deficiency Triple negative breast cancer |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| authorswithroles_txt_mv |
Belli, Carmen @@aut@@ Duso, Bruno Achutti @@oth@@ Ferraro, Emanuela @@oth@@ Curigliano, Giuseppe @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV004843835 |
| dewey-sort |
3610 |
| id |
ELV046533842 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV046533842</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626013856.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.breast.2019.02.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000596.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV046533842</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0960-9776(19)30026-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.65</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Belli, Carmen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Homologous recombination deficiency in triple negative breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Platinum agent</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BRCA mutations</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PARP inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Homologous recombination deficiency</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Triple negative breast cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Duso, Bruno Achutti</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferraro, Emanuela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Curigliano, Giuseppe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Yang, Lin ELSEVIER</subfield><subfield code="t">The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004843835</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:45</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:15-21</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.breast.2019.02.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.65</subfield><subfield code="j">Chirurgie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">45</subfield><subfield code="j">2019</subfield><subfield code="h">15-21</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| author |
Belli, Carmen |
| spellingShingle |
Belli, Carmen ddc 610 bkl 44.65 Elsevier Platinum agent Elsevier BRCA mutations Elsevier PARP inhibitors Elsevier Homologous recombination deficiency Elsevier Triple negative breast cancer Homologous recombination deficiency in triple negative breast cancer |
| authorStr |
Belli, Carmen |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV004843835 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.65 bkl Homologous recombination deficiency in triple negative breast cancer Platinum agent Elsevier BRCA mutations Elsevier PARP inhibitors Elsevier Homologous recombination deficiency Elsevier Triple negative breast cancer Elsevier |
| topic |
ddc 610 bkl 44.65 Elsevier Platinum agent Elsevier BRCA mutations Elsevier PARP inhibitors Elsevier Homologous recombination deficiency Elsevier Triple negative breast cancer |
| topic_unstemmed |
ddc 610 bkl 44.65 Elsevier Platinum agent Elsevier BRCA mutations Elsevier PARP inhibitors Elsevier Homologous recombination deficiency Elsevier Triple negative breast cancer |
| topic_browse |
ddc 610 bkl 44.65 Elsevier Platinum agent Elsevier BRCA mutations Elsevier PARP inhibitors Elsevier Homologous recombination deficiency Elsevier Triple negative breast cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
b a d ba bad e f ef g c gc |
| hierarchy_parent_title |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| hierarchy_parent_id |
ELV004843835 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV004843835 |
| title |
Homologous recombination deficiency in triple negative breast cancer |
| ctrlnum |
(DE-627)ELV046533842 (ELSEVIER)S0960-9776(19)30026-8 |
| title_full |
Homologous recombination deficiency in triple negative breast cancer |
| author_sort |
Belli, Carmen |
| journal |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| journalStr |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
15 |
| author_browse |
Belli, Carmen |
| container_volume |
45 |
| physical |
7 |
| class |
610 VZ 44.65 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Belli, Carmen |
| doi_str_mv |
10.1016/j.breast.2019.02.007 |
| dewey-full |
610 |
| title_sort |
homologous recombination deficiency in triple negative breast cancer |
| title_auth |
Homologous recombination deficiency in triple negative breast cancer |
| abstract |
Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. |
| abstractGer |
Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. |
| abstract_unstemmed |
Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Homologous recombination deficiency in triple negative breast cancer |
| url |
https://doi.org/10.1016/j.breast.2019.02.007 |
| remote_bool |
true |
| author2 |
Duso, Bruno Achutti Ferraro, Emanuela Curigliano, Giuseppe |
| author2Str |
Duso, Bruno Achutti Ferraro, Emanuela Curigliano, Giuseppe |
| ppnlink |
ELV004843835 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.breast.2019.02.007 |
| up_date |
2024-07-06T20:28:53.450Z |
| _version_ |
1803862916152164352 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV046533842</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626013856.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.breast.2019.02.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000596.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV046533842</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0960-9776(19)30026-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.65</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Belli, Carmen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Homologous recombination deficiency in triple negative breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Platinum agent</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BRCA mutations</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PARP inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Homologous recombination deficiency</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Triple negative breast cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Duso, Bruno Achutti</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferraro, Emanuela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Curigliano, Giuseppe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Yang, Lin ELSEVIER</subfield><subfield code="t">The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004843835</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:45</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:15-21</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.breast.2019.02.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.65</subfield><subfield code="j">Chirurgie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">45</subfield><subfield code="j">2019</subfield><subfield code="h">15-21</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| score |
7.39999 |